Deutsche Bank Starts Halozyme Therapeutics (HALO) at Buy

November 3, 2016 6:46 AM EDT
Get Alerts HALO Hot Sheet
Price: $11.53 -0.86%

Rating Summary:
    13 Buy, 0 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade HALO Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Deutsche Bank initiated coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Buy rating and a price target of $12. Analyst Andrew Peters noted favorable upside skew.

Peters explained, "While the largely de-risked ENHANZE platform provides a reasonable valuation floor on HALO shares only modestly below current levels, we look to the Stage-2 data from the ongoing ph2 Study 202 of lead asset PEGPH20 in pancreatic cancer as a true binary event for the stock. While we understand bearish concerns about trial design and potential limited interpretability, we believe, however, that given current sentiment on the program, even positive trends confirming the HA-high hypothesis should drive upside to the stock. Further, despite our overall view that every read-out seen so far has been supportive of a strong drug effect, we remain quite cautious as well in our modeling. Despite our conservatism, however, we see a highly favorable risk/reward at current levels and believe the current market outlook is overly cautious on the late-stage program, especially in the context of the ENHAZE royalty business."

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $8.32 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Deutsche Bank

Add Your Comment